The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from PR Newswire

Regeneron Announces June 2012 Investor Conference Presentations

Wednesday, May 30, 2012

Regeneron Announces June 2012 Investor Conference Presentations09:30 EDT Wednesday, May 30, 2012TARRYTOWN, N.Y., May 30, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast management presentations at the following investor conferences:Goldman Sachs Global Healthcare Conference 2012 at 7:00 p.m. Eastern Time (4:00 p.m. Pacific Time) on Tuesday, June 5, 2012 Jefferies 2012 Global Healthcare Conference at 10:30 a.m. Eastern Time on Thursday, June 7, 2012The sessions may be accessed through the Company's web site, www.regeneron.com, on the 'Events and Presentations' page.  Archived versions of the presentations will be available for thirty days after the live webcasts.  Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets two products in the United States, ARCALYST® (rilonacept) Injection for Subcutaneous Use and EYLEA® (aflibercept) Injection, and has filed regulatory applications with the U.S. Food and Drug Administration (FDA) for second indications for each of these products.   A regulatory application has also been submitted to the FDA for the product candidate ZALTRAP® (aflibercept) Concentrate for Intravenous Infusion.  Phase 3 studies are in progress with EYLEA® in a third indication, and with product candidate sarilumab.  Earlier-stage clinical programs are underway with nine additional monoclonal antibodies.  Regeneron has active research and development programs in many disease areas, including ophthalmology, inflammation, cancer, and hypercholesterolemia.  Additional information and recent news releases are available on the Regeneron web site at www.regeneron.com.Contact Information: Manisha Narasimhan, Ph.D.Peter DworkinInvestor RelationsCorporate Communications                       914-847-5126914-847-7640                       manisha.narasimhan@regeneron.com peter.dworkin@regeneron.comSOURCE Regeneron Pharmaceuticals, Inc.